Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187848 · ClinicalTrials.gov registry record · Phase 1
Evaluation of SAR408701 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 254
- Enrollment target
NCT02187848: Clinical Trial Phase 1 study, sponsored by Sanofi.
NCT02187848 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 254 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (323% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02187848, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 254 participants
- Enrollment target
Study Summary
Primary Objectives: * To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy, once every 2 weeks (with and without a loading dose at Cycle 1) to patients with advanced solid tumors (Main Escalation and Loading Dose Escalation Q2W). * To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy, once every 3 weeks to patients with advanced solid tumors (Escalation Q3W Cycle). * To assess efficacy according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) (Expansion Phase) when SAR408701 is administered once every 2 weeks with or without a loading dose at Cycle 1. Secondary Objectives: * To characterize the overall safety profile of SAR408701. * To characterize the pharmacokinetic (PK) profile of SAR408701 and of its potential circulating derivatives. * To identify the recommended phase 2 dose (RP2D) of SAR408701. * To assess the potential immunogenicity of SAR408701.
Interventions
- DRUG SAR408701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2014-07-23 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 1 |
Why NCT02187848 stopped before completion
NCT02187848 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (323% higher).
The record links to 0 conditions, and to 1 intervention - of which SAR408701 is the first listed.
NCT02187848 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02187848 about?
NCT02187848 is a clinical study titled "Evaluation of SAR408701 in Patients With Advanced Solid Tumors". Primary Objectives: * To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy, once every 2 weeks (with and without a loading dose at Cycle 1) to patients with advanced solid tumors (Main Escalation and Loading Dose Escalation Q2W). * To determine the maximum tolerate...
What is the current status of trial NCT02187848?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 254 participants. The study started on 2014-07-23. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT02187848?
The interventions under investigation include: SAR408701 (DRUG).
Who is sponsoring clinical trial NCT02187848?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02187848's enrollment target sits among peer trials
254 168th of 2000 higher than 1,832 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI